Full Press Release Details
Investor Webinar Presentation
Melbourne, Australia, February
8, 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to
advise our Chief Executive Officer, Steven Lydeamore will be presenting at the Monsoon Communications Investor function on Thursday, 8th
February in Sydney, Australia.
A copy of the presentation being
made is included below.
Authorised for release by the Board of Immuron Limited.
Chief Executive Officer
orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting traveller's diarrhoea, a
digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce. Travelan is a highly
purified tabletised preparation of hyperimmune bovine antibodies and other factors, which when taken with meals bind to diarrhoea-causing
bacteria and prevent colonisation and the pathology associated with traveller's diarrhoea. In Australia, Travelan
is a listed medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Traveller's
Diarrhoea, reduce the risk of minor gastrointestinal disorders and is antimicrobial. In Canada, Travelan is a licensed
natural health product (NPN 80046016) and is indicated to reduce the risk of Traveller's Diarrhoea. In the U.S., Travelan
is sold as a dietary supplement for digestive tract protection.
About Traveller's Diarrhoea
Traveller's Diarrhoea is a
gastrointestinal infection with symptoms that include loose, watery (and occasionally bloody) stools, abdominal cramping, bloating, and
fever, Enteropathogenic bacteria are responsible for most cases, with enterotoxigenic Escherichia coli (ETEC) playing a dominant
causative role. Campylobacter spp. are also responsible for a significant proportion of cases. The more serious infections with Salmonella
spp. the bacillary dysentery organisms belonging to Shigella spp. and Vibrio spp. (the causative agent of cholera) are often confused
with Traveller's Diarrhoea as they may be contracted while travelling and initial symptoms are often indistinguishable.
Immuron Limited (ASX: IMC, NASDAQ:
IMRN), is an Australian biopharmaceutical company focused on developing and commercialising orally delivered targeted polyclonal antibodies
for the treatment of infectious diseases.
For more information visit: http://www.immuron.com
FORWARD-LOOKING STATEMENTS:
This press release may
contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of
the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to
our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking
statements are based on management's current expectations and are subject to risks and uncertainties that could negatively
affect our business, operating results, financial condition and stock value. Factors that could cause actual results to differ
materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and
maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities;
risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing;
our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products
under development; our need for substantial additional funds; government regulation; patent and intellectual property matters;
competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or
any changes in events, conditions or circumstances on which any such statement is based, except as required by law.